Drug Type Small molecule drug |
Synonyms Levodroproizine, Levodropropizine Buccal, DF-526 + [11] |
Target- |
Action modulators |
Mechanism Neuropeptides modulators(Neuropeptides modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Italy (01 Jan 1988), |
Regulation- |
Molecular FormulaC13H20N2O2 |
InChIKeyPTVWPYVOOKLBCG-ZDUSSCGKSA-N |
CAS Registry99291-25-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Levodropropizine |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Cough | Italy | 01 Jan 1988 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bronchitis | Phase 3 | United States | 01 Jan 2017 | |
| Acute upper respiratory infection | Phase 3 | Russia | 09 Nov 2016 | |
| Dry cough | Phase 3 | Russia | 09 Nov 2016 | |
| Refractory chronic cough | Clinical | Italy | 12 Feb 2014 |
Phase 3 | 184 | (Levopront® Syrup 30 mg/5 ml) | ftweszpghn = bfdvhicvwu unbpkdposa (dgkeoromjn, auonloswie - zojfnbxwug) View more | - | 15 Apr 2024 | ||
(Libexin® 100 mg Tablets) | ftweszpghn = nmzzgqjsjs unbpkdposa (dgkeoromjn, przdlpcbjw - otkpsweqdq) View more |





